Clinical trials: Extensive-stage SCLC
Solid Tumor, Extensive-stage Small-cell Lung Cancer
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
An open-label, two-part Phase I/Ib study of RP12146 in adult patients with locally advanced or metastatic solid tumors. The first part (Part 1) is a Phase I dose-escalation, 3+3 design, open-label, MTD determination study and…
- Conditions
- Solid Tumor, Extensive-stage Small-cell Lung Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT05002868
- Testing
- RP12146
- Where
- 6 sites in Czechia, Poland
- Volunteers
- 23 people
- Sponsor
- Rhizen Pharmaceuticals SA
SCLC, Extensive Stage, Advanced Solid Tumors
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, multi-cohort investigation exploring the efficacy and safety of ABP1011T tablets in participants with specific target solid tumors, providing a foundation for subsequent clinical research.
- Trial name
- ABP1011T-03 (NCT07321574)
- Testing
- ABP1011T
- Where
- 8 sites in China
- Volunteers
- 110 people
- Sponsor
- Shanghai AB PharmaTech Ltd.
Small Cell Lung Cancer
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC).
- Trial name
- NCT02289690
- Testing
- Veliparib, Carboplatin, Etoposide
- Where
- 62 sites in United States, Australia and 10 more
- Volunteers
- 221 people
- Sponsor
- AbbVie
Lung Cancer
PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544674
- Testing
- PR104, F-18-fluoromisonidazole
- Where
- 18 sites in United States
- Volunteers
- 5 people
- Sponsor
- Proacta, Incorporated
Small Cell Lung Cancer
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and…
- Trial name
- NCT03041311
- Testing
- Trilaciclib, Carboplatin, Etoposide
- Where
- 45 sites in United States, Bulgaria and 5 more
- Volunteers
- 107 people
- Sponsor
- G1 Therapeutics, Inc.
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or…
- Trial name
- NCT06449209
- Testing
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide
- Where
- 64 sites in United States, Australia and 3 more
- Volunteers
- 110 people
- Sponsor
- BioNTech SE
Extensive-Stage Small Cell Lung Cancer
A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 in combination with a checkpoint inhibitor compared to standard first-line therapy in participants with Extensive-Stage Small Cell Lung Cancer.
- Trial name
- NCT07796100
- Testing
- ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance
- Volunteers
- 530 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Lung Neoplasms
ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.
The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.
- Trial name
- NCT00051506
- Testing
- ALIMTA, carboplatin, cisplatin
- Where
- 8 sites in United States
- Sponsor
- Eli Lilly and Company
Extensive Stage Small Cell Lung Cancer
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
This is a randomized, controlled, open-label, multicenter clinical study to evaluate the efficacy and safety of carboplatin/cisplatin + etoposide + benmelstobart sequential benmelstobart combined with anlotinib versus…
- Trial name
- NCT06897579
- Testing
- Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule, Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection
- Where
- 32 sites in China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Small Cell Lung Cancer
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors (±chemotherapy) as first-line therapy in Participants with extensive stage small…
- Trial name
- NCT07231445
- Testing
- ZG006, Serplulimab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Small Cell Lung Carcinoma
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Small cell lung cancer (SCLC), characterized by rapid proliferation, high growth fraction and early development of metastases, is the most aggressive form of lung cancer.
- Trial name
- ARSENAL (NCT05683977)
- Testing
- durvalumab
- Where
- 34 sites in France
- Volunteers
- 254 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
- Trial name
- (DeLLphi-310) (NCT06898957)
- Testing
- YL201, Tarlatamab, Durvalumab
- Where
- 36 sites in United States, Canada and 8 more
- Volunteers
- 29 people
- Sponsor
- Amgen
Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell…
- Trial name
- NCT05680922
- Testing
- LB2102
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Legend Biotech USA Inc
Small-Cell Lung Cancer
Study of AZD2811 + Durvalumab in ES-SCLC
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with…
- Trial name
- TAZMAN (NCT04745689)
- Testing
- Durvalumab, AZD2811, Carboplatin
- Where
- 12 sites in United States, Poland and 2 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain.
- Trial name
- SEZanne (NCT07155174)
- Testing
- ABBV-706, Atezolizumab, Etoposide
- Where
- 70 sites in United States, Belgium and 11 more
- Volunteers
- 180 people
- Sponsor
- AbbVie
Extensive-stage Small-cell Lung Cancer
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with extensive-stage small cell lung cancer.
- Trial name
- NCT06437509
- Testing
- BL-B01D1, PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Small Cell Lung Carcinoma
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with…
- Trial name
- IMpower133 (NCT02763579)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Etoposide
- Where
- 114 sites in United States, Australia and 19 more
- Volunteers
- 503 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer, Small Cell
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
- Trial name
- NCT00316186
- Testing
- topotecan, carboplatin
- Where
- 13 sites in United States, Poland
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
- Trial name
- DeLLphi-305 (NCT06211036)
- Testing
- Tarlatamab, Durvalumab
- Where
- 219 sites in United States, Argentina and 27 more
- Volunteers
- 563 people
- Sponsor
- Amgen
Extensive-stage Small-cell Lung Cancer
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not…
- Trial name
- NCT07459634
- Testing
- Lurbinectedin, Durvalumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jazz Pharmaceuticals